2025 AACR | Rongchang Pharmaceutical makes its debut at AACR Annual Meeting! Poster displays 2 preclinical research findings

On April 7, 2025, Yantai Rongchang Pharmaceutical Co., Ltd. (hereinafter referred to as "Rongchang Pharmaceutical") announced that it will release the latest preclinical research results of its independently developed pan RAS (on) inhibitors RCZY-680/RCZY-690 and Menin inhibitor RCZY-711 in the form of a poster at the 2025 American Association for Cancer Research (AACR) Annual Meeting. This is also the first time that Rongchang Pharmaceutical has presented its research results at the AACR annual meeting.

The AACR Annual Conference is one of the most authoritative academic conferences in the world. The current AACR conference will be held in Chicago, USA from April 25th to 30th, 2025. The molecules of the two projects showcased by Rongchang Pharmaceutical at this annual conference have impressive preclinical data and demonstrated the best potential in their class in mouse models. The relevant report information is as follows: Title: RCZY-690 and RCZY-680: Novel, highly potent, and orally bioavailable, tri-complex pan RAS-MULTI(ON) inhibitors with distinctive oral pharmacokinetic profiles, exhibiting broad anti-tumor activities in CDX modelsSession Category Conference Category: Molecular/Cellular Biology and Genetics Session Title/Conference Title: Growth Factors, Receptors, and GTP ase SignalingLocation Location/: Poster Section 10 Poster Board Number/Poster Number: 7 Published Abstract Number/Publication Abstract Number: 239 Session Date and Time/Conference Date and Time: 27 April, 2025, 2:00 PM -5:00 PM

Title: RCZY-711 a novel, highly potent, and orally bioavailable menin-MLL inhibitor with superior efficacy in preclinical acute leukemia modelsSession Category/ Conference Category: Molecular/Cellular Biology and Genetics Session Title/Conference Title: Gene Regulation and Transcription Factors 2Location/Presentation Location: Poster Section 10 Poster Board Number/Poster Number: 16 Published Abstract Number/Publication Abstract Number: 1419Session Date and Time/Conference Date and Time: 28 April, 2025, 9:00 AM -12:00 PM Regarding AACR, the American Association for Cancer Research (AACR) Annual Meeting is one of the oldest and largest academic conferences in cancer research worldwide. The conference focuses on various aspects of high-quality tumor research and innovation, and is the focal point of global tumor research, gathering the most cutting-edge research achievements in the field of tumors. AACR currently has over 58000 members in 141 countries and regions, with a mission to prevent and treat cancer through research, education, communication, collaboration, scientific policy and advocacy, and funding for cancer research. Rongchang Pharmaceutical was founded in 1993 and is headquartered in Yantai, China. It is a modern pharmaceutical enterprise that integrates research and development, production, sales, and service, spanning four major fields: modern traditional Chinese medicine, small molecule and biopharmaceuticals, biopharmaceutical research and development and production services (CDMO), biopharmaceutical enterprises, and project incubation. The founder and management team of the company have years of experience in research and management of top multinational pharmaceutical companies, and have participated in the development of multiple clinical and marketed new drugs. The subsidiaries and spin off companies established over the years include Rongchang Biotechnology, Yeda International Biomedical Innovation Incubation Center, Yantai Mabirui International Biotechnology, Yantai Sepp Biotechnology, Rongchang Pharmaceutical (Zibo), etc. Rongchang Pharmaceutical's small molecule R&D department focuses on the research and development of new cancer drugs, with tumor targeted precision therapy and tumor immunotherapy drugs as the core. It is committed to developing potential first in class or best in class innovative drugs with clear biological mechanisms and significant unmet clinical needs. It has now formed a research and development pipeline layout covering solid tumors and hematological tumors.

For more information, please visit www.rongchang.com.